CoChat

CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs

Open access
Vandervorst, Fenne, Van Deun, Laura, Van Dycke, Annelies, Paemeleire, Koen, Reuter, Uwe, Schoenen, Jean, Versijpt, Jan · 2021 · The Journal of Headache and Pain

The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.

Abstract

Background: Several drugs are available for the preventive treatment of both episodic and chronic migraine. The choice of which therapy to initiate first, second, or third is not straightforward and is based on multiple factors, including general efficacy, tolerability, potential for serious adverse events, comorbid conditions, and costs. Recently, a new class of migraine preventive drugs was introduced, i.e. monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor. Methods: The present article summarizes the evidence gathered with this new migraine preventive drug class from randomized placebo-controlled clinical trials. It further puts this into perspective next to the evidence gained by the most widely used agents for the prevention of episodic and chronic migraine with an emphasis on efficacy and the robustness with which this efficacy signal was obtained. Results: Although being a relatively new class of migraine preventive drugs, monoclonal antibodies blocking the CGRP pathway have an efficacy which is at least comparable if not higher than those of the currently used preventive drugs. Moreover, the robustness of this efficacy signal is substantiated by several randomized clinical trials each including large numbers of patients. In addition, because of their excellent tolerability and with long-term safety data emerging, they seem to have an unprecedented efficacy over adverse effect profile, clearly resulting in an added value for migraine prevention. Conclusions: Balancing the data presented in the current manuscript with additional data concerning long term safety on the one hand and cost issues on the other hand, can be of particular use to health policy makers to implement this new drug class in the prevention of migraine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s10194-021-01335-2

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 dropouts due to AEs and change in MMD versus placebo in episodic migraine patients. The size of the circle corresponds to the number of patients that were treated with the prophylactic agent across all RCTs. can: candesartan; ami: amitriptyline; top: topiramate: val: valproate; CGRP: CGRP mAb; β: beta-blockers; RCT: randomised controlled trial; MMD: monthly migraine days
Fig. 1 dropouts due to AEs and change in MMD versus placebo in episodic migraine patients. The size of the circle corresponds to the number of patients that were treated with the prophylactic agent across all RCTs. can: candesartan; ami: amitriptyline; top: topiramate: val: valproate; CGRP: CGRP mAb; β: beta-blockers; RCT: randomised controlled trial; MMD: monthly migraine daysCC BY · PubMed Central
Fig. 2 dropouts due to AEs and change in MMD versus placebo in chronic migraine patients. The size of the circle corresponds to the number of patients that were treated with the prophylactic agent across all RCTs. top: topiramate; onabot: onabotulinumtoxinA; CGRP: CGRP MAb; RCT: randomised controlled trial; MMD: monthly migraine days
Fig. 2 dropouts due to AEs and change in MMD versus placebo in chronic migraine patients. The size of the circle corresponds to the number of patients that were treated with the prophylactic agent across all RCTs. top: topiramate; onabot: onabotulinumtoxinA; CGRP: CGRP MAb; RCT: randomised controlled trial; MMD: monthly migraine daysCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 94 references

Research works printed but not linked: 2

  1. Mulleners WM, Haan J, Dekker F, Jko T, Wbo H, Tqfdjgjfl B et al (2010) Preventieve behandeling van migraine. Ned Tijdschr Geneeskd 154:1–9
  2. Solomon GDSA (1986) Verapamil and propranolol in migraine prophylaxis: a double-blind, cross over study. Headache. 26:325

Cited by

See all 121

Metadata

Authors
Vandervorst, F., Van Deun, L., Van Dycke, A., Paemeleire, K., Reuter, U., Schoenen, J., & Versijpt, J.
Affiliations
  • Vrije Universiteit Brussel (BE)
  • Ghent University Hospital (BE)
  • Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
  • University of Liège (BE)
Corresponding author
Versijpt, Jan
Venue
The Journal of Headache and Pain
Published
2021-10-25
Volume
22
Issue
1
Pages
128-128
ISSN
  • 1129-2369 (ISSN-L)
  • 1129-2377
OpenAlex
W3208701883
Cited by
121
References
94
Citations by year
2026: 12 · 2025: 19 · 2024: 19 · 2023: 36 · 2022: 34 · 2021: 1
FWCI
16.14
Type
journal article
Language
en
Open access
Licence
Locations
  • The Journal of Headache and Pain (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Migraine and Headache Studies
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
  • Health Sciences › Dentistry › Oral Surgery › Temporomandibular Joint Disorders
Keywords
migraine prophylaxis, CGRP monoclonal antibodies, calcitonin gene-related peptide, CGRP receptor antagonists, episodic migraine, chronic migraine, drug efficacy, tolerability, adverse events, long-term safety, cost-effectiveness, health policy
MeSH terms
Antibodies, Monoclonal, Calcitonin, Pharmaceutical Preparations, Humans, Migraine Disorders, Calcitonin Gene-Related Peptide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. https://app.cochat.ai/papers/10.1186/s10194-021-01335-2
The paper
Vandervorst, F., Van Deun, L., Van Dycke, A., Paemeleire, K., Reuter, U., Schoenen, J., & Versijpt, J. (2021). CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. The Journal of Headache and Pain. https://doi.org/10.1186/s10194-021-01335-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.